Ovarian cancer is the commonest gynaecological cancer causing death. Young (1975) estimates that one hundred thousand American women died from this malignancy in the last decade. It is disappointing that optimal therapy for local as well as disseminated disease is still not known. The difficulties that face the surgeon, radiotherapist and chemotherapist in ovarian carcinoma include the problem of diagnosing the condition early, being sure that the tumour is completely eradicated and detecting early recurrence. This is partly due to the biological behaviour of the tumour, with its propensity to early transcoelomic spread to sites such as the diaphragmatic surface of the liver, where it is difficult to detect. In only one quarter of women is the disease diagnosed while still confined to the ovaries; more than half have abdominal extension of the disease or metastases at diagnosis.
The International Federation of Gynaecologists and Obstetricians (FIGO) staging is given in Table I . Stage I corresponds to growth macroscopically limited to both ovaries, stage II when the growth involves local extension within the pelvis, stage III when the abdominal organs are involved and stage IV when extra-abdominal or liver metastases are present.
In assessing the results of comparative trials it is important to show that the groups are comparable for stage, histology, and, as emphasized by Bush et al. (1977) , the success of the initial operation to resect the tumour.
In a comprehensive review of ovarian carcinoma Tobias & Griffiths (1976) have assessed the five-year survival rates at the various FIGO stages ( Table 2 ). The five-year survival has varied in these cumulative figures, from 60% for stage I disease to less than 5~o in stage III and stage IV disease.
Advanced ovarian carcinoma
The drugs most commonly used in ovarian carcinoma have been the alkylating agents. These agents include nitrogen mustard, cyclophosphamide, chlorambucil and phenylalanine mustard or melphalan. Nitrogen mustard was used by Parker et al. (1970) , 0.2 mgjkg being given intravenously on two successive days every four weeks; 39 out of 88 patients achieved an objective response. Cyclophosphamide is more convenient as it can be given orally. Decker et al. (1968) used 400 mg i.v. daily for four days then reduced the dose to 150 mg daily by mouth and obtained an objective improvement in 22 out of 104 (21%) patients. Beck & Boyes (1968) , using smaller doses by mouth and some intravenous cyclophosphamide, were more Successful, obtaining response rates of 37 out of 78 (47%) and 25 out of 48 (52~~) respectively. Chlorambucil is welltolerated, having few side effects apart from bone marrow suppression. Masterson & Nelson (1965) gave a 6-week course of 0.2 mgjkg per day orally and achieved 140 complete responses in 280 patients (50%). Phenylalanine mustard was reported by Smith & Rutledge (1970) to be effective either intravenously or orally. When given orally in a dose of I mg/kg divided over five days (that is, approximately 10 mg/day for five days in the average patient), 100 complete responses were seen in nearly 500 patients (20%). A comparison of the results obtained with alkylating agents, and the preliminary data obtained in small series of patients treated with either antimetabolites or newer agents, is given in Table 3 . The alkylating agents have also been given intraperitoneally but there is little evidence that they are any more effective given in this way than by other routes, and they may well be less effective (Smith & Rutledge 1970) .
The introduction of new agents in ovarian carcinoma has been relatively slow. This has probably been due to these drugs being less readily available to gynaecologists, and to their understandable reluctance to use drugs with unpleasant side effects at a late stage of the disease. It is only recently that drugs such as hexamethylmelamine, adriamycin and platinum diamminodichloride have entered proper trial.
Hexamethylmelamine, although derived from the alkylating agent trimethylmelamine, is not thought to act as an alkylating agent. It will achieve responses in patients who have become resistant to alkylating agents (Wampler et al. 1972) . Using an oral daily dose of 8 mg/kg responses were obtained in three out of seven patients (42%). Toxic effects limiting dosage were gastrointestinal or neurological rather than haematological. It must be emphasized that many of the trials of these new agents are in patients who have already received standard chemotherapy, and therefore the response rate is lower than if the drug was being used de novo. DeVita et al. (1976) gained a response rate of 21 out of 54 (39%) and concluded that the drug is definitely active against carcinoma of the ovary.
Adriamycin (Doxorubicin) is an antitumour antibiotic that is effective against a wide range of malignancies. Although it has toxic effects on the marrow and gastrointestinal tract, its major toxic effect is on the myocardium. It is effective in patients with carcinoma of the ovary and can produce responses even in those who have become resistant to alkylating agents. Slavik (1975) , reviewing the activity of adriamycin in a number of gynaecological malignancies, suggested that the high response rate seen in earlier small series was not being confirmed.
Analysis of 43 cases treated showed that a 17%response rate was obtained in serous cystadenocarcinoma. DeVita et al. (1976) quote a response rate of 18out of 48 (38%) and suggest that the drug is definitely active. In a randomized trial against melphalan the response rate was higher for adriamycin, but the duration of response was only three months compared with 6.5 months for melphalan (De Palo et al. 1974). Another chemotherapeutic agent in which there is great interest is platinum diamminodichloride. This organic platinum compound has been shown to have activity in testicular tumours, ovarian adenocarcinoma and tumours of the head and neck. Its activity has been reviewed by Rozencweig et al. (1977) . Some eight trials are in progress of platinum diamminodichloride as a single agent and response rates of 40-66% are being achieved in carcinoma of the ovary. One of the most convincing studies so far is a phase II study by Wiltshaw & Kroner (1976) who treated 34 patients who were resistant to conventional chemotherapy. Even in these patients they achieved nine responses (26.5%) when 30 mgjm 2jdaywas given every two or three weeks. The major toxic effects included myelosuppression, renal function impairment, neuropathy, deafness and nausea and vomiting. The gastrointestinal symptoms may prove difficult to control.
It would be of the utmost importance to know whether combinations of these new agents with each other or with more conventional drugs such as cyclophosphamide, melphalan or 5fluorouracil are superior to single drug treatments. There is so far very little conclusive evidence that combinations of drugs are superior to one drug alone, although there are good theoretical reasons why this should be so in ovarian cancer. A prospective randomized trial of cyclophosphamide, actinomycin D and 5-fluorouracil compared with melphalan showed no significant difference (Smith et al. 1972 ). Piver et al. (1975 report a randomized study in which 66 patients were also treated either by melphalan or by cyclophosphamide, actinomycin D and 5-fluorouracil. Although the overall response rate was not very different in the two groups, 45% for melphalan and 63% for the combination, the complete response rate was significantly higher in the combination therapy patients: 40% compared to 18% with melphalan alone (Table 4 ). The careful investigation of drug combinations, and comparison with a single agent, are of great importance. The Medical Research Council of Great Britain is investigating the response rate to cyclophosphamide given alone and continuously, compared with intermittent cyclophosphamide, hexamethylmelamine and methotrexate, and a study is in progress at the National Cancer Institute comparing melphalan with hexamethylmelamine, cyclophosphamide, 5-fluorouracil and methotrexate. The latter has recently been published, showing an advantage for the combination (Young et al. 1978) .
In a small series of patients with ovarian carcinoma, of whom the majority had been treated previously with alkylating agents, C H Collis (1977, personal communication) in our Unit has found a response rate of five out of 10 patients treated with adriamycin, cyclophosphamide and platinum diamminodichloride, which would suggest that this particular combination is worth further investigation.
The use of this combination of drugs has recently been reported by Bruckner et al. (1978) , who treated 24 patients with stage III or stage IV ovarian adenocarcinoma in whom prior chemotherapy had failed. Even in this previously treated group, adriamycin, cyclophosphamide and platinum produced objective responses in 12 of the 24 cases, and six additional patients had subjective improvement. No cases of nephrotoxicity occurred in the study where saline diuresis was obtained by giving 1000-2000 ml of fluid over a 24-hour period.
Early ovarian cancer: adjuvant chemotherapy trials Randomized prospective trials of combination versus single drug regimes are few. Even less is known about the effect ofcombining radiotherapy and chemotherapy. The two best studies are conflicting. Kottmeier (1968) compared total abdominal radiotherapy alone with total abdominal radiotherapy plus thiotepa. Median survivals of 13 months for the combination of treatments compared with seven months for radiotherapy alone. Johnson et al. (1972) found no significant difference in the median survival when cyclophosphamide was used instead of thiotepa. In the current MRC trial on early ovarian cancer adjuvant treatment with chlorambucil is to be compared with hexamethylmelamine.
In an interim analysis of 279 patients with epithelial carcinoma of the ovary, Bush et al. (1977) have emphasized the importance of the stage of the tumour and of the completeness of the surgical removal of primary disease. In their studies the largest differences in survival occurred between the groups which had complete and the groups which had incomplete surgical removal: complete surgical removal was attended with a far better survival rate. If this factor is confirmed as an important determinant, radical reassessment of the results of previous prospective trials comparing radiotherapy and chemotherapy will be necessary. Smith et al. (1975) have suggested, for example, that for patients with localized ovarian carcinoma results so far with irradiation and chemotherapy are similar. Bush et al. (1977) dispute this because Smith's series (Smith et al. 1975 ) contained, in their view, more early stage patients in the melphalan arm of the trial and the results would therefore be biased. In the study by Bush et al. (1977) chlorambucil did not seem to be able to decrease the risk of upper abdominal metastases, and they advocate abdominal irradiation to above the level of the diaphragm. At three and a half years in stage IB or stage II patients who had similar operative procedures, there was no significant difference in survival between those patients who had pelvic irradiation alone, pelvic irradiation and chlorambucil, or pelvic irradiation and abdominal strip irradiation to above the diaphragm. It is evident that much needs to be done to define the best management of early disease.
In summary, alkylating agents have been the best available drugs for use in the chemotherapy of ovarian cancer. Newer agents such as hexamethylmelamine, adriamycin and platinum diamminodichloride are now entering trial. The best adjuvant chemotherapy remains a matter for urgent clinical investigation and is now the subject of one of the current MRC trials. In stage III and IV disease a determined attempt has to be made to evaluate all available drugs in ovarian cancer and to set up properly randomized studies to test the efficacy of single versus multidrug combinations.
